Loading...
Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma and...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE-Hindawi Access to Research
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3170848/ https://ncbi.nlm.nih.gov/pubmed/21994874 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4061/2011/873548 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|